Exploring Oral Systemic Therapies for Plaque Psoriasis: Efficacy, Safety, and Clinical Considerations

Lauren Miller, MPAS, PA-C; Jayme M. Heim, MSN FNP-BC, and Kirk Gautier, PA-C, discuss recent advancements in plaque psoriasis treatment, focusing on novel oral systemic therapies like the TYK-2 inhibitor deucravacitinib and its clinical trial data, to inform therapeutic decisions for this systemic disease.

Related Content:

ClinicalMedcast PodcastsVideo Series

Jack Arnold, MBBS: Honing in on ANA-RMD Classifications to Improve Research

LUNA, OPTIC Data Support Long-Term Benefit of Ixo-Vec for Wet AMD

Psoriasis Severity, Systemic Inflammation Associated with Cardiovascular Disease